Early versus conventional treatment for patent ductus arteriosus in preterm infants.

Abstract

OBJECTIVE:

After the introduction of a new protocol based on the early treatment with indomethacin for patent ductus arteriosus, the objective of this study was to assess the safety and efficacy of this new practice in comparison with the safety and efficacy of the conventional treatment in a high-risk population.

STUDY DESIGN:

We conducted a retrospective cohort study including 154 newborns with an average gestational age of 26.4 weeks (1.37 standard deviation) and an average birth weight of 855 g (201.5 standard deviation). A statistically descriptive analysis was performed with SPSS Statistics Pack version 17.0.

RESULTS AND CONCLUSIONS:

We did not find any statistically significant differences in the clinical features of the two treatment groups, nor in the main efficacy, morbidity, and mortality results.

• Authors: Júlia Candel-Pau, Ángeles Linde Sillo, Félix Castillo Salinas, Ermengol Coma Redon, Queralt Ferrer Menduiña, Dimpna C Albert
• Journal: American journal of perinatology (Am J Perinatol) Vol. 30 Issue 4 Pg. 289-95 (Apr 2013) ISSN: 1098-8785 [Electronic] United States
• PMID: 22918677 (Publication Type: Comparative Study, Journal Article)
• Copyright: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chemical References

• Cardiovascular Agents
• Indomethacin

Topics

• Cardiovascular Agents (therapeutic use)
• Chi-Square Distribution
• Cohort Studies
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Ductus Arteriosus, Patent (diagnostic imaging, drug therapy, mortality)
• Echocardiography, Doppler
• Female
• Follow-Up Studies
• Gestational Age
• Humans
• Indomethacin (therapeutic use)
• Infant, Newborn
• Infant, Premature
• Male
• Retrospective Studies
• Risk Assessment
• Survival Rate
• Time Factors
• Treatment Outcome